Oxford Nanopore Technologies Plc develops proprietary technology platform for the electronic analysis of single molecules. The firm has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
Follow-Up Questions
Oxford Nanopore Technologies PLC의 CEO는 누구입니까?
Dr. Gurdial Sanghera은 2005부터 회사에 합류한 Oxford Nanopore Technologies PLC의 Chief Executive Officer입니다.
ONTTF 주식의 가격 성능은 어떻습니까?
ONTTF의 현재 가격은 $1.92이며, 전 거래일에 decreased 0% 하였습니다.
Oxford Nanopore Technologies PLC의 주요 사업 주제나 업종은 무엇입니까?
Oxford Nanopore Technologies PLC은 Life Sciences Tools & Services 업종에 속하며, 해당 부문은 Health Care입니다
Oxford Nanopore Technologies PLC의 시가총액은 얼마입니까?
Oxford Nanopore Technologies PLC의 현재 시가총액은 $1.8B입니다
Oxford Nanopore Technologies PLC는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 15명의 분석가가 Oxford Nanopore Technologies PLC에 대한 분석 평가를 실시했으며, 이는 5명의 강력한 매수, 11명의 매수, 3명의 보유, 1명의 매도, 그리고 5명의 강력한 매도를 포함합니다
